Literature DB >> 7508161

Pathological characteristics of surgically removed craniopharyngiomas: analysis of 131 cases.

G T Szeifert1, L Sipos, M Horváth, M H Sarker, O Major, B Salomváry, S Czirják, K Bálint, F Slowik, L Kolonics.   

Abstract

Pathological specimens of 131 surgically removed craniopharyngiomas were obtained from the registry of the National Institute of Neurosurgery, Budapest between 1977 and 1991. The cases were reviewed statistically with reference to their gross and microscopic features and clinical characteristics. Macroscopically, 34% of the tumours were cystic, 23% solid and 43% mixed. Histologically, 38% of the cases belonged to the adamantinous group, 26% were squamous epithelial type, 15% were combined, that is expressing the characteristics of both. In 21% of the cases the surgically removed samples did not contain enough material for correct histopathologic classification. There was no recurrence in the group with the squamous epithelial type tumours, while 59% of the adamantinous, and 36% of the combined craniopharyngiomas recurred. The 5-year survival proportion was 73% at the squamous epithelial, 60% in the adamantinous, and 55% at the combined histological types.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508161     DOI: 10.1007/bf01401137

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  10 in total

1.  Abscess formation in Rathke's cleft cyst.

Authors:  L Bognàr; G T Szeifert; I Fedorcsàk; E Pàsztor
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

2.  Symptomatic Rathke's cleft cyst. Morphological study with light and electron microscopy and tissue culture.

Authors:  J Yoshida; T Kobayashi; N Kageyama; M Kanzaki
Journal:  J Neurosurg       Date:  1977-09       Impact factor: 5.115

3.  Aggressive surgical management of craniopharyngiomas in children.

Authors:  H J Hoffman; M De Silva; R P Humphreys; J M Drake; M L Smith; S I Blaser
Journal:  J Neurosurg       Date:  1992-01       Impact factor: 5.115

4.  Forty-five years experience with the craniopharyngiomas.

Authors:  E A Kahn; H H Gosch; J F Seeger; S P Hicks
Journal:  Surg Neurol       Date:  1973-01

5.  Craniopharyngiomas: a clinical and pathological review.

Authors:  C K Petito; U DeGirolami; K M Earle
Journal:  Cancer       Date:  1976-04       Impact factor: 6.860

6.  Correlation of clinical and pathological features in surgically treated craniopharyngiomas.

Authors:  T E Adamson; O D Wiestler; P Kleihues; M G Yaşargil
Journal:  J Neurosurg       Date:  1990-07       Impact factor: 5.115

7.  Could craniopharyngiomas produce pituitary hormones?

Authors:  G T Szeifert; E Pásztor
Journal:  Neurol Res       Date:  1993-02       Impact factor: 2.448

8.  Suprasellar papillary squamous epithelioma ("papillary craniopharyngioma").

Authors:  F Giangaspero; P C Burger; D R Osborne; R B Stein
Journal:  Am J Surg Pathol       Date:  1984-01       Impact factor: 6.394

9.  Secretory component of cystic craniopharyngiomas: a mucino-histochemical and electron-microscopic study.

Authors:  G T Szeifert; J Julow; M Szabolcs; F Slowik; K Bálint; E Pásztor
Journal:  Surg Neurol       Date:  1991-10

10.  Demonstration of light chain monotypia in B cell non-Hodgkin's lymphomas using unfixed freeze-dried and formalin-fixed trypsinised paraffin sections.

Authors:  Z Nemes; T Thomázy; G Szeifert
Journal:  J Clin Pathol       Date:  1983-08       Impact factor: 3.411

  10 in total
  15 in total

Review 1.  Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.

Authors:  Ruth Prieto; José M Pascual
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

2.  Ectopic recurrence of a craniopharyngioma in a 15-year-old girl 9 years after surgery and conventional radiotherapy: case report.

Authors:  Maria Elfving; Johan Lundgren; Elisabet Englund; Lars-Göran Strömblad; Eva-Marie Erfurth
Journal:  Childs Nerv Syst       Date:  2011-01-11       Impact factor: 1.475

Review 3.  Risk-adapted, long-term management in childhood-onset craniopharyngioma.

Authors:  Hermann L Müller
Journal:  Pituitary       Date:  2017-04       Impact factor: 4.107

4.  Regression of a large solid papillary craniopharyngioma following fractionated external radiotherapy.

Authors:  J Honegger; G G Grabenbauer; W Paulus; R Fahlbusch
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

Review 5.  Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review.

Authors:  Josephine R Coury; Brittany N Davis; Christoforos P Koumas; Giovanna S Manzano; Amir R Dehdashti
Journal:  Neurosurg Rev       Date:  2018-04-17       Impact factor: 3.042

6.  Craniopharyngioma: a clinicopathological study of 141 cases.

Authors:  Seyed Mohammad Tavangar; Bagher Larijani; Ali Mahta; Seyed Mehdi Abdolahzadeh Hosseini; Masoud Mehrazine; Fatemeh Bandarian
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

7.  Recurrence in pediatric craniopharyngiomas: analysis of clinical and histological features.

Authors:  Deepak Kumar Gupta; B K Ojha; Chitra Sarkar; Ashok Kumar Mahapatra; B S Sharma; V S Mehta
Journal:  Childs Nerv Syst       Date:  2005-05-14       Impact factor: 1.475

8.  Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma.

Authors:  M Losa; A Vimercati; S Acerno; R L Barzaghi; P Mortini; F Mangili; M R Terreni; G Santambrogio; M Giovanelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

9.  Comparative immunohistochemical assessment of craniopharyngioma and related lesions.

Authors:  Brian H Le; Javad Towfighi; Silloo B Kapadia; M Beatriz S Lopes
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

10.  Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth.

Authors:  Christina Stache; Annett Hölsken; Rudolf Fahlbusch; Jörg Flitsch; Sven-Martin Schlaffer; Michael Buchfelder; Rolf Buslei
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.